Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.

Pharmacogenetics and genomics - 1 Apr 2014

Barratt Daniel T, Bandak Benedikte, Klepstad Pål, Dale Ola, Kaasa Stein, Christrup Lona L, Tuke Jonathan, Somogyi Andrew A

Abstract excerpt

OBJECTIVE: This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl. METHODS: CYP3A4*22 and CYP3A5*3 polymorphisms were analysed in 620 cancer pain patients receiving transdermal fentanyl (12.5-700 μg/h) from the European...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to ATP Binding Cassette Transporter, Subfamily D, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP-Binding Cassette Transporters

Share to Cytochrome P-450 CYP3A

Share to Fentanyl

Share to Genetic Association Studies

Share to Neoplasms

Source

Identifiers

PMID: 24469018
DOI: 10.1097/FPC.0000000000000032

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.PMID 24469018Read ↗

Scoping review of associations between cytochrome P450 3A4/5 single nucleotide polymorphisms and risk factors for fentanyl overdose.Semantic proximity Read ↗

Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.Semantic proximity Read ↗

Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.Semantic proximity Read ↗

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Semantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl.Semantic proximity Read ↗

Review of Opioid Pharmacogenetics and Considerations for Pain ManagementSemantic proximity Read ↗

The Role of Clinical Pharmacogenetics and Opioid Interactions in Optimizing Treatment in Clinical PracticeSemantic proximity Read ↗

Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.Semantic proximity Read ↗

Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Semantic proximity Read ↗

Pharmacogenetics in palliative care.Semantic proximity Read ↗

Genetics and Opioids: Towards More Appropriate Prescription in Cancer PainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.